Single User
£3750
PDF
48 pages

Overactive Bladder Forecast in 12 Major Markets 2017-2027


Overactive Bladder (OAB) is a (relatively) common, disabling condition associated with significant negative impact on quality of life, sleep and mental health. It is characterised as a sudden, strong uncontrollable urge to urinate.

This report provides the current prevalent population for Overactive Bladder across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Overactive Bladder have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Patients with OAB often also have other bladder-related symptoms such as:

  • Nocturia
  • Urgency issues
  • Frequency issues
  • Issues with voiding
  • Urge urinary incontinence (UUI)

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Overactive Bladder market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Overactive Bladder and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Overactive Bladder’s prevalent population.
  • Identify sub-populations within Overactive Bladder which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Overactive Bladder patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line prevalence for Overactive Bladder
  • Features of Overactive Bladder patients
  • Prevalence of clinically diagnosed OAB
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • Criteria for the Diagnosis of Overactive Bladder
  • Prevalence of Overactive Bladder, total (000s)
  • Prevalence of Overactive Bladder, males (000s)
  • Prevalence of Overactive Bladder, females (000s)
  • Severity of Symptom Bother, total (000s)
  • OAB patients with Nocturia, total (000s)
  • OAB patients with Urgency, total (000s)
  • OAB patients with Frequency, total (000s)
  • OAB patients with UUI, total (000s)
  • Prevalence of Clinically diagnosed OAB, total (000s)
  • Prevalence of Clinically diagnosed OAB, males (000s)
  • Prevalence of Clinically diagnosed OAB, females (000s)
  • Clinically diagnosed OAB Urge Incontinence status, total (000s)
  • Clinically diagnosed OAB patients by symptoms, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • USA Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • Canada Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • Canada Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • France Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • France Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • Germany Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • Germany Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • Italy Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • Italy Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • Spain Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • Spain Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • UK Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • UK Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • Japan Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • Japan Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • India Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • India Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • China Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • China Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
  • Russia Prevalence of Overactive Bladder by 5-yr age cohort, males (000s)
  • Russia Prevalence of Overactive Bladder by 5-yr age cohort, females (000s)
Brazil, Canada, China, France, Germany, India, Italy, Japan, Russian Federation, Spain, United Kingdom, United States of America